In This Article:
As the United States stock market navigates a complex landscape of inflation data and interest rate adjustments, investors are exploring diverse opportunities across various sectors. The term 'penny stocks' may seem outdated, but these smaller or newer companies can still offer potential for growth when they possess strong financial fundamentals. In this article, we explore three U.S. penny stocks that stand out for their financial resilience and potential to deliver value to investors seeking to uncover promising opportunities in the market.
Top 10 Penny Stocks In The United States
Name | Share Price | Market Cap | Financial Health Rating |
QuantaSing Group (NasdaqGM:QSG) | $3.08 | $99.16M | ★★★★★★ |
Inter & Co (NasdaqGS:INTR) | $4.36 | $1.91B | ★★★★☆☆ |
BAB (OTCPK:BABB) | $0.89 | $6.46M | ★★★★★★ |
Pangaea Logistics Solutions (NasdaqCM:PANL) | $4.84 | $227.01M | ★★★★★☆ |
ZTEST Electronics (OTCPK:ZTST.F) | $0.2109 | $7.76M | ★★★★★★ |
Imperial Petroleum (NasdaqCM:IMPP) | $2.84 | $86.14M | ★★★★★★ |
Golden Growers Cooperative (OTCPK:GGRO.U) | $4.50 | $67.38M | ★★★★★★ |
Smith Micro Software (NasdaqCM:SMSI) | $0.9694 | $17.19M | ★★★★★☆ |
CBAK Energy Technology (NasdaqCM:CBAT) | $0.78 | $70.15M | ★★★★★☆ |
Safe Bulkers (NYSE:SB) | $3.51 | $374.79M | ★★★★☆☆ |
Click here to see the full list of 742 stocks from our US Penny Stocks screener.
We'll examine a selection from our screener results.
SAB Biotherapeutics
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing human polyclonal immunotherapeutic antibodies for immune system disorders and infectious diseases, with a market cap of $42.92 million.
Operations: SAB Biotherapeutics generates its revenue from the biotechnology segment, totaling $1.51 million.
Market Cap: $42.92M
SAB Biotherapeutics, Inc., with a market cap of US$42.92 million, has faced increasing net losses, reporting a US$10.35 million loss in Q3 2024 compared to US$5.1 million the previous year. Despite being debt-free and having short-term assets exceeding liabilities, SAB is unprofitable with a negative return on equity and less than one year of cash runway. The company's revenue decreased to US$1.21 million for the first nine months of 2024 from US$1.93 million in the prior period, indicating challenges in achieving profitability amidst high share price volatility and declining earnings forecasts over the next three years.
-
Dive into the specifics of SAB Biotherapeutics here with our thorough balance sheet health report.
-
Understand SAB Biotherapeutics' earnings outlook by examining our growth report.
Vista Gold
Simply Wall St Financial Health Rating: ★★★★★★